Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01354977 · ClinicalTrials.gov registry record · Phase 2

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

A Phase 2 study, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01354977: Completed Phase 2 study, sponsored by Albert Einstein College of Medicine.

NCT01354977 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01354977, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

Resveratrol is a natural polyphenol (a compound containing a phenol functional group) that can be found in many plants. The purpose of this research is to study the effects of resveratrol on the action of insulin (a hormone produced in the body by the pancreas that regulates the amount of sugar in the blood), fat accumulation, and inflammation in the body.

Primary Outcome

We will measure peripheral insulin sensitivity by determining the rate of glucose uptake (RD). RD will be measured using a 6 hours stepped pancreatic clamp study procedure under various treatment conditions (eg, resveratrol or placebo). by monitoring changes in the level of a non-radioactive, naturally occurring form of glucose (sugar).

Interventions

  • DRUG Resveratrol

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-03
Est. Completion 2017-09-15
Phase Phase 2
Albert Einstein College of Medicine

175 total trials

What the finished NCT01354977 record still lists

NCT01354977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 1 intervention - of which Resveratrol is the first listed.

NCT01354977 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01354977 about?

NCT01354977 is a clinical study titled "Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans". Resveratrol is a natural polyphenol (a compound containing a phenol functional group) that can be found in many plants. The purpose of this research is to study the effects of resveratrol on the action of insulin (a hormone produced in the body by the pancreas that regulates the amount of sugar in t...

What is the current status of trial NCT01354977?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-03. Estimated completion is 2017-09-15.

What interventions are being tested in trial NCT01354977?

The interventions under investigation include: Resveratrol (DRUG).

Who is sponsoring clinical trial NCT01354977?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01354977's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01354977, the US trial registry maintained by the National Library of Medicine. NCT01354977 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.